GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 02:56:00 12/02/2026 pm IST			5-day change	1st Jan Change
2,129.50 ^GBX	-0.95%		-2.25%	+16.80%

12:53pm	Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant	RE
11/02	Bernstein Upbeat on GSK Amid Upcoming Catalysts; Price Target, Forecasts Revised	MT

GSK : Gets a Neutral rating from Goldman Sachs

Published on 06/30/2025 at 04:23 pm IST

MarketScreener with dpa-AFX Analyser

GSK PLC

-0.95%

Goldman Sachs's research confirms his advice and maintains his neutral opinion on the stock. The target price is set at 1580 versus 1560 GBX.

Latest news about GSK plc

12:53pm	Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant	RE
11/02	Bernstein Upbeat on GSK Amid Upcoming Catalysts; Price Target, Forecasts Revised	MT
11/02	FDA refuses to review Moderna's influenza vaccine application	RE
10/02	European Stocks Mostly Lower in Tuesday Trading; UK Regulator Seeks Views on Apple, Google Competition Commitments	MT
10/02	Quest Diagnostics Incorporated announces an Increase in Equity Buyback	CI
10/02	Tranche Update on Quest Diagnostics Incorporated's Equity Buyback Plan announced on October 20, 2010.	CI
10/02	GSK's RSV Vaccine Arexvy Accepted for Regulatory Review in China for Older Adults	MT
10/02	GSK RSV vaccine Arexvy accepted for review in China for adults over 60	AN
10/02	GSK says regulatory decision on Arexvy expected in 2027	RE
10/02	Chinese Regulator Accepts GSK's Arexvy Vaccine for Review	MT
10/02	GSK plc's RSV Vaccine Accepts for Review by China's Center for Drug Evaluation for the Prevention of Lower Respiratory Syncytial Virus Disease	CI
09/02	Deutsche cuts Unilever; Jefferies cuts Greggs	AN
06/02	European Stocks Track Higher in Friday Trading; Stellantis Tanks on $26.5 Billion Write-Down	MT
06/02	GSK Chair Jonathan Symonds buys GBP53,000 in shares	AN
06/02	GSK plc Announces Nucala (Mepolizumab) Approval by European Commission for Treatment of Chronic Obstructive Pulmonary Disease	CI
06/02	Markets Ask the Obvious Question
06/02	GSK Says European Commission Approves Nucala to Treat Chronic Obstructive Pulmonary Disease	MT
06/02	Oddo BHF cuts Wizz Air and Ryanair	AN
06/02	FTSE 100 falls as AI fears pressure data stocks	AN
06/02	EU regulator greenlights GSK lung disease therapy Nucala	AN
06/02	UK house prices rise more than expected in January	AN
06/02	GSK Wins EU Nod for Nucala in Uncontrolled Chronic Obstructive PulmonaryDisease	MT
06/02	GSK : Receives a Sell rating from JP Morgan	ZD
06/02	GSK says Nucala COPD approved by the European Commission	RE
06/02	Markets are seasick

GSK plc is a global biopharma company. The Companyâ€™s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Employees

68,629

Sector

Pharmaceuticals

Calendar

29/04 - Q1 2026 Earnings Release

More about the company